Literature DB >> 6211333

Experimental canine parvovirus infection in dogs.

R V Pollock.   

Abstract

In specific pathogen-free dogs, clinical signs of experimental canine parvovirus infection were mild, inconsistent and transient. Clinical signs were more pronounced in conventionally-raised dogs, but the severe disease reported in field cases was not reproduced in either group. A pronounced plasma viremia occurred on the 2nd to 4th day post-infection (d.p.i.) in dogs challenged oronasally. Antibody was detectable on the 5th d.p.i. Marked pyrexia was rare, but a significant temperature rise usually coincided with the appearance of antibody and the cessation of viremia. Significant lymphopenia, but not leukopenia, occurred on the 3rd to 7th d.p.i. Virus could be readily isolated from fecal matter on the 3rd to 8th d.p.i.; a few dogs continued to shed virus for up to 12 days. In dogs challenged parenterally, the onset of elevated temperatures, viral shed and antibody production occurred 24-48 hours sooner. Convalescent dogs were no longer contagious for susceptible contact animals 25 days or longer after challenge, although infectious virus persisted in feces for more than 6 months at room temperature. Active giardiasis seemed to exacerbate the clinical syndrome, although treatment with corticosteroids or anti-thymocyte serum did not.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6211333

Source DB:  PubMed          Journal:  Cornell Vet        ISSN: 0010-8901


  24 in total

1.  Studies on canine parvovirus infection: preparation of challenge virus.

Authors:  L Macartney; I A McCandlish; H Thompson; H J Cornwell
Journal:  Res Vet Sci       Date:  1988-09       Impact factor: 2.534

2.  Purified feline and canine transferrin receptors reveal complex interactions with the capsids of canine and feline parvoviruses that correspond to their host ranges.

Authors:  Laura M Palermo; Susan L Hafenstein; Colin R Parrish
Journal:  J Virol       Date:  2006-09       Impact factor: 5.103

3.  First peptide vaccine providing protection against viral infection in the target animal: studies of canine parvovirus in dogs.

Authors:  J P Langeveld; J I Casal; A D Osterhaus; E Cortés; R de Swart; C Vela; K Dalsgaard; W C Puijk; W M Schaaper; R H Meloen
Journal:  J Virol       Date:  1994-07       Impact factor: 5.103

4.  Interactions Between Carnivores in Madagascar and the Risk of Disease Transmission.

Authors:  Fidisoa Rasambainarivo; Zach J Farris; Hertz Andrianalizah; Patricia G Parker
Journal:  Ecohealth       Date:  2017-10-16       Impact factor: 3.184

5.  Analysis of experimental mink enteritis virus infection in mink: in situ hybridization, serology, and histopathology.

Authors:  A Uttenthal; S Larsen; E Lund; M E Bloom; T Storgård; S Alexandersen
Journal:  J Virol       Date:  1990-06       Impact factor: 5.103

Review 6.  Canine parvovirus.

Authors:  R V Pollock; M J Coyne
Journal:  Vet Clin North Am Small Anim Pract       Date:  1993-05       Impact factor: 2.093

7.  The seroprevalence of canine parvovirus-2 in a selected sample of the canine population in ontario.

Authors:  P S Carman; R C Povey
Journal:  Can Vet J       Date:  1984-06       Impact factor: 1.008

8.  The duration of immunity to an inactivated adjuvanted canine parvovirus vaccine. A 52 and 64 week postvaccination challenge study.

Authors:  R C Povey; P S Carman; E Ewert
Journal:  Can Vet J       Date:  1983-08       Impact factor: 1.008

9.  Genotyping and pathobiologic characterization of canine parvovirus circulating in Nanjing, China.

Authors:  Yanbing Zhao; Yan Lin; Xujian Zeng; Chengping Lu; Jiafa Hou
Journal:  Virol J       Date:  2013-08-29       Impact factor: 4.099

10.  Canine parvovirus VP2 protein expressed in silkworm pupae self-assembles into virus-like particles with high immunogenicity.

Authors:  Hao Feng; Gui-qiu Hu; Hua-lei Wang; Meng Liang; Hongru Liang; He Guo; Pingsen Zhao; Yu-jiao Yang; Xue-xing Zheng; Zhi-fang Zhang; Yong-kun Zhao; Yu-wei Gao; Song-tao Yang; Xian-zhu Xia
Journal:  PLoS One       Date:  2014-01-17       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.